Literature DB >> 14512305

Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning.

Julia C Morris1, Melissa Conerly, Bobbie Thomasson, Jan Storek, Stanley R Riddell, Hans-Peter Kiem.   

Abstract

Lentiviral vectors are increasingly being used for transferring genes into hematopoietic stem cells (HSCs) due to their ability to transduce nondividing cells. Whereas results in in vitro studies and the nonobese diabetic/severe combined immunodeficiency (NOD/SCID) model have been highly encouraging, studies in large animals have not confirmed the superior transduction of HSCs using lentiviral vectors versus oncoretroviral vectors. In contrast to the stable gene marking we have consistently achieved with oncoretroviral vectors in animals that received myeloablative conditioning, we observed the complete disappearance of genetically modified enhanced green or yellow fluorescent protein-expressing cells in 5 baboons that received transplants of HSCs transduced with lentiviral vectors alone or in combination with oncoretroviral vectors. Immune responses to transgene products have been found to be involved in the disappearance of gene-modified cells after nonmyeloablative conditioning. Thus, we examined whether the disappearance of gene-modified cells after ablative conditioning may be due to an immune response. In 4 of 5 animals, cytotoxic T lymphocytes specific for the transgene protein were readily detected, demonstrating that immune reactions were responsible for the disappearance of the gene-marked cells in the animals. In summary, we report the induction of transgene-specific immune responses after transplantation of lentivirally transduced repopulating cells in a myeloablative setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512305     DOI: 10.1182/blood-2003-07-2324

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

Authors:  Alice F Tarantal; Francesca Giannoni; C Chang I Lee; Jennifer Wherley; Teiko Sumiyoshi; Michele Martinez; Christoph A Kahl; David Elashoff; Stan G Louie; Donald B Kohn
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

2.  Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector.

Authors:  S E Suter; T A Gouthro; P A McSweeney; R A Nash; M E Haskins; P J Felsburg; P S Henthorn
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

3.  Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells.

Authors:  Jakub Tolar; Matthew J O'shaughnessy; Angela Panoskaltsis-Mortari; Ron T McElmurry; Scott Bell; Megan Riddle; R Scott McIvor; Stephen R Yant; Mark A Kay; Diane Krause; Catherine M Verfaillie; Bruce R Blazar
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  In vitro culture during retroviral transduction improves thymic repopulation and output after total body irradiation and autologous peripheral blood progenitor cell transplantation in rhesus macaques.

Authors:  Karin Loré; Ruth Seggewiss; F Javier Guenaga; Stefania Pittaluga; Robert E Donahue; Allen Krouse; Mark E Metzger; Richard A Koup; Cavan Reilly; Daniel C Douek; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2006-02-23       Impact factor: 6.277

5.  An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.

Authors:  Joseph E Doherty; Lauren E Woodard; Adham S Bear; Aaron E Foster; Matthew H Wilson
Journal:  FASEB J       Date:  2013-06-10       Impact factor: 5.191

Review 6.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

7.  In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.

Authors:  Maximilian Richter; Kamola Saydaminova; Roma Yumul; Rohini Krishnan; Jing Liu; Eniko-Eva Nagy; Manvendra Singh; Zsuzsanna Izsvák; Roberto Cattaneo; Wolfgang Uckert; Donna Palmer; Philip Ng; Kevin G Haworth; Hans-Peter Kiem; Anja Ehrhardt; Thalia Papayannopoulou; André Lieber
Journal:  Blood       Date:  2016-08-23       Impact factor: 22.113

Review 8.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

10.  Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.

Authors:  Herena Eixarch; Alba Gómez; Elisabeth Kádár; Mónica George; Nuria Martínez; Carmen Espejo; Jordi Pétriz; Ramon Gimeno; Jordi Barquinero
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.